Archives
JAK Inhibitors and Endothelial Cardiovascular Risk
JAK Inhibitors and Endothelial Cardiovascular Risk
Study Background and Research Question
Patients with rheumatoid arthritis have an elevated burden of cardiovascular disease, a relationship commonly associated with persistent systemic inflammation. The reference study by Zavoriti and Miossec focuses on the vascular endothelium, which is not simply a passive barrier: endothelial activation influences leukocyte recruitment, coagulation, fibrinolysis, and vascular integrity. Inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-17A (IL-17A) can act together to increase inflammatory mediators, adhesion molecules, and procoagulant signals.
The research question was whether different approved Janus kinase inhibitors produce comparable or distinct effects on endothelial dysfunction during inflammatory stimulation. This question is clinically relevant because JAK inhibitors share a broad therapeutic class but differ in kinase selectivity, approved indications, and pharmacologic behavior. The authors therefore examined whether suppressing inflammatory cytokines was accompanied by favorable changes in adhesion, coagulation, anticoagulation, and cell survival endpoints. The full report is available in ACR Open Rheumatology.
A key biological distinction underlies the study. TNF and IL-17A do not directly signal through the JAK-STAT signaling pathway, whereas cytokines such as interleukin-6, interleukin-23, and interferon-γ do. Consequently, the experiment was not a simple test of direct blockade of the initiating cytokine receptors. Instead, it assessed how JAK inhibition influences a broader inflammatory endothelial state that may include pathway cross-talk and secondary signaling effects.
Key Innovation from the Reference Study
The principal innovation is the comparative, multi-endpoint design. Rather than treating all JAK inhibitors as interchangeable anti-inflammatory agents, the study evaluated tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib in the same general endothelial inflammatory framework. This creates a more informative contrast between shared class effects and compound-specific responses.
The study also moves beyond soluble cytokines. IL-6 and IL-8 release provided measures of inflammatory output, while expression of VCAM-1, ICAM-1, and E-selectin represented endothelial adhesiveness and potential leukocyte recruitment. Tissue factor and thrombomodulin addressed the balance between procoagulant and anticoagulant phenotypes. Annexin V staining supplied a separate measure of endothelial apoptosis. Taken together, these endpoints allowed the authors to ask whether an inhibitor reduced inflammation while leaving other vascular risks unchanged or even worsened.
This integrated framing is important for immune regulation research. A compound can lower inflammatory mediator release without normalizing the endothelial surface or restoring anticoagulant capacity. The paper therefore contributes a caution against using one favorable biomarker, such as IL-6 reduction, as a surrogate for overall vascular benefit.
Conceptual Study Design and Evidence Scope
The investigators used human vascular endothelial cells exposed to a combined TNF and IL-17A inflammatory challenge. Parallel conditions included treatment with each of the six JAK inhibitors or the corresponding untreated inflammatory comparison. The compounds were evaluated at two reported exposure levels, allowing the authors to examine whether effects were consistent across the tested range or changed with exposure.
At the measurement level, enzyme-linked immunosorbent assays quantified secreted IL-6 and IL-8. Quantitative reverse-transcriptase polymerase chain reaction assessed changes in genes related to endothelial adhesion, coagulation, and fibrinolysis. Annexin V staining was used to evaluate apoptotic cells. This is a conceptual overview of the published design rather than a laboratory protocol.
The design has several strengths. All compounds were examined against the same cytokine context, which reduces some sources of comparison bias. The use of human endothelial cells gives the findings direct relevance to vascular biology, while the combination of inflammatory, adhesion, hemostatic, and survival readouts captures several dimensions of endothelial dysfunction. At the same time, the evidence remains preclinical and cell-based. It establishes comparative responses in an in vitro model, not cardiovascular event rates or net clinical benefit in patients.
Core Findings and Why They Matter
Shared suppression of inflammatory output
All six JAK inhibitors reduced IL-6 release from endothelial cells stimulated with TNF plus IL-17A. This common response supports the idea that JAK inhibition can influence inflammatory amplification even when the initiating cytokines do not directly use JAK-STAT signaling. However, the effects on IL-8 were more selective: only baricitinib and fedratinib reduced IL-8 overproduction at the lower tested exposure level. The divergence between IL-6 and IL-8 shows that cytokine suppression was not uniform across compounds or inflammatory mediators.
For inflammatory disorder research, this distinction matters because IL-6 and IL-8 represent different aspects of endothelial activation. A shared effect on one cytokine does not establish a shared effect on chemokine production, cell adhesion, or thrombosis-related biology.
Compound-specific effects on adhesion molecules
Fedratinib reduced the cytokine-associated increase in VCAM-1 and E-selectin at both reported exposure levels. Tofacitinib reduced ICAM-1 and E-selectin induction at the lower level. These results suggest that some inhibitors can attenuate selected endothelial activation markers under the study conditions.
The higher tested exposure produced a more complex pattern. Tofacitinib, baricitinib, upadacitinib, peficitinib, and ruxolitinib enhanced the TNF plus IL-17A-associated induction of VCAM-1 and ICAM-1. This finding is particularly important because it separates anti-inflammatory activity from endothelial surface behavior. It does not mean that these agents universally increase adhesion molecules in patients; rather, it demonstrates that the direction of response in this model depended on the compound, endpoint, and exposure level.
Procoagulant and anticoagulant balance
Peficitinib and fedratinib reduced tissue factor up-regulation at both tested levels, while ruxolitinib showed this effect only at the lower level. In contrast, none of the JAK inhibitors prevented the cytokine-associated decrease in thrombomodulin. The combined result is not a complete restoration of endothelial hemostatic balance. A reduction in tissue factor may be favorable for one part of the response, but persistent loss of thrombomodulin indicates that the anticoagulant arm remains impaired in the model.
This is one of the paper's most meaningful contributions to cardiovascular safety interpretation. Procoagulant and anticoagulant markers should be considered together rather than summarized as a single vascular outcome. The study also supports caution when translating cytokine results into assumptions about thrombosis biology.
Apoptosis and cytotoxicity
Fedratinib and peficitinib produced proapoptotic and cytotoxic effects in the endothelial model. This finding adds an important safety dimension because endothelial cell loss can aggravate barrier disruption and vascular dysfunction. It also illustrates why apoptosis should be measured alongside inflammatory gene expression: a lower inflammatory signal may coexist with cellular injury.
Tofacitinib, often discussed in immune regulation research as a JAK3-oriented compound with activity across JAK family members, was not uniformly protective across the vascular endpoints examined. Its effects included reduced selected adhesion markers at the lower tested exposure and increased VCAM-1 and ICAM-1 induction at the higher tested exposure. Its relevance to lymphocyte proliferation inhibition is pharmacologic context, not an endpoint tested in this endothelial study.
Comparison with Existing Internal Articles
The internal article JAK Inhibitors and Endothelial Response to Inflammatory Cytokines is thematically aligned with the reference paper because it emphasizes adhesion molecules, inflammatory signaling, and apoptosis. It can serve as a companion overview, but the 2025 study should remain the primary evidence source for the comparative findings reported here.
A second related resource, Tofacitinib Citrate and JAK-STAT Immune Modulation, provides broader mechanistic context for tofacitinib and immune signaling. Its scope is wider than the endothelial comparison. In contrast, Zavoriti and Miossec provide the direct evidence for how tofacitinib behaved relative to five other JAK inhibitors under a defined inflammatory endothelial challenge. These resources should therefore be read as complementary editorial context, not as interchangeable evidence.
Limitations and Transferability
The most important limitation is the in vitro setting. Cultured endothelial cells do not reproduce the full physiology of rheumatoid arthritis, myeloproliferative neoplasms, or other inflammatory disorders. They lack interactions with circulating leukocytes, platelets, smooth muscle cells, liver metabolism, tissue-specific cytokine gradients, and blood flow. Because thrombosis is a multicellular and dynamic process, changes in endothelial transcripts or Annexin V staining cannot be equated directly with clinical cardiovascular events.
The cytokine challenge also represents a particular inflammatory state. TNF plus IL-17A is biologically relevant to endothelial activation, but patient inflammation is heterogeneous and may include interferons, interleukins, complement factors, oxidative stress, and metabolic influences. Results may therefore differ in other cell sources, disease contexts, or cytokine combinations.
Exposure interpretation is another boundary. The reported comparisons used defined concentrations in vitro, and the direction of some responses changed between the lower and higher tested levels. Cellular exposure in a dish is not automatically equivalent to free drug exposure in human vascular tissue. Pharmacokinetics, protein binding, active metabolites, tissue distribution, and disease-specific dosing all require separate evaluation. The study also does not establish why individual inhibitors produced divergent effects. Differences may reflect kinase selectivity, cellular target engagement, concentration-dependent off-target activity, or compound-specific effects that cannot be resolved from the reported endpoints alone.
Finally, the study was not designed to rank overall clinical safety among the six agents. Its value is comparative and mechanistic: it identifies patterns that deserve confirmation in more complex models and clinical datasets. The evidence supports a multidimensional vascular assessment, but it does not justify broad claims that one JAK inhibitor is universally protective or harmful.
Research Support Resources
For material sourcing related to the paper's tofacitinib comparator, researchers can review Tofacitinib citrate (CP-690550 citrate), SKU A4135. This product reference should be considered alongside the source paper's model-specific evidence and does not change the study's nonclinical limitations.